Videos from Genomic Health, Inc

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

  

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with Oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® Results. The results showed that adding genomic information provided by the Oncotype DX®Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria. The study was the largest adjuvant breast cancer study ever and it included patients from US, Canada, Peru, Ireland, Australia, and New Zealand. It was published in the New England Journal of Medicine in September 2015, read the article.

Adjuvant Therapy in Early-Stage ER-Positive, HER2-Negative Invasive Breast Cancer

 

Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2-negative breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour.

Other videos

  • Video on the role of genomic tests in personalised medicine for colon cancer with Prof David Kerr - Oxford Clinical Trials Research Unit, Oxford, UK. Professor David Kerr talks to ecancerTV about the Oncotype DX® Colon Cancer Assay which gives useful additional information on possible patient selection for treatment, particularly in those with a bad prognosis. Professor Kerr explains how a patient's Gene signature can identify patients with a higher vs. lower risk of cancer recurrence, and how this information can be used to determine which patients are most likely to benefit from additional chemotherapy. This helps to tailor treatments for colon cancer to the right patient at the right time with the right disease.
  • Video on the role of genomic testing in personalised medicine for breast cancer with Professor David Miles. The role of Oncotype DX® in the management of breast cancer was discussed. Oncotype DX® offers a novel diagnostic test for women with node negative, ER positive and HER 2- invasive breast cancer. It scores the breast tumour on 21 different genes involved in breast cancer, giving a Recurrence Score (between 0 and 100), which shows the likelihood of breast cancer returning within 10 years of the original diagnosis.
Last update: 14 October 2015